Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Therapeutic effect of subcutaneous injection of low dose recombinant human granulocyte-macrophage colony-stimulating factor on pulmonary alveolar proteinosis

Fig. 2

Patient screening process, * Methods to exclude secondary PAP: Medical history was inquired to exclude genetic factors; to inquire whether there is a history of industrial dust exposure and ask pneumonologists to help exclude occupational pneumoconiosis; Microbial examination was performed to exclude secondary PAP changes caused by viruses, bacteria, fungi, tuberculosis and other infections through sputum, bronchoalveolar lavage fluid, blood and other samples

Back to article page